الفهرس 
HEMOPHILIA AOnly 14 pages are availabe for public view
 |  | from | 203 |  |  |
| | | from | 203 | | |
Abstract
A major complication in the treatment of HA is the
development of antibodies that inactivate the procoagulant
activity of FVIII, increasing the risk of bleeding, physical
disability and mortality. Inhibitors occur mainly in children soon
after onset of therapy with FVIII concentrate. The incidence of
inhibitors in HA patients varies, mainly dependent on the
genotype.
The measurement of the FVIII inhibitor is achieved by
the employment of the Bethesda assay. This is based on the
ability of the patient’s plasma containing the FVIII inhibitor to
inactivate FVIII present in normal pooled plasma.
This work aimed to evaluate the relationship between
inhibitor status of haemophilia patients and their QoL and
degree of arthropathy and to compare the orthopaedic status of
patients with/without inhibitors.
The current study was carried on 40 hemophilic patients.
All were subjected to full history, through clinical examination,
laboratory investigations, including: CBC, FVIII and FVIII
inhibitor measurement, X-ray and Dexa.